Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292275 · ClinicalTrials.gov registry record · NA
Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote Monitoring
A NA study, sponsored by Amgen.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04292275 is a NA study that was terminated before completion, run by Amgen. The registered enrollment target is 18 participants.
The verdict
NCT04292275, a NA study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
A study evaluating the impact of remotely collected data, measured using digital technologies, on the use of guideline-recommended heart failure therapy in adult participants with heart failure.
Interventions
- OTHER Standard of Care
- DEVICE Biobeat Wrist Watch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2021-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04292275
The ClinicalTrials.gov registry entry for NCT04292275 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04292275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04292275 about?
NCT04292275 is a clinical study titled "Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote Monitoring". A study evaluating the impact of remotely collected data, measured using digital technologies, on the use of guideline-recommended heart failure therapy in adult participants with heart failure.
What is the current status of trial NCT04292275?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2020-03-06. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04292275?
The interventions under investigation include: Standard of Care (OTHER), Biobeat Wrist Watch (DEVICE).
Who is sponsoring clinical trial NCT04292275?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.